Jane V. Harper,Namir J. Hassan,Nathaniel Liddy,Tara Mahon,Giovanna Bossi,Katherine Adams,Jessie Gavarret,Frayne Bianchi,Nikolai Lissin,Peter Molloy,Yi Li,Nick Pumphrey,Brian Cameron,Malkit Sami,Emma Baston,Rebecca Ashfield,Andrew Johnson,Annelise Vuidepot,Yvonne Mcgrath,Penio Todorov,Samantha Paston,Milos Aleksic,Alison Legg,Debbie Wright,Rebecca Dennis,Andrew K. Sewell,David A. Price,Naomi Harwood,Anna Lissina,Emma Gostik,Carl June,Michael Kalos,Gabriela Pleas,Deborah Sutton,Daniel Williams,Bent Jakobsen

Abstract:In the last decade, major efforts in the fight against cancer have focused on galvanizing the adaptive immune system to kill tumors. Many of these endeavors are based on the development and clinical use of monoclonal antibodies (mAb) which are the most successful class of immune modulating agent identified to date. While mAbs show promise against certain cancers, their specificity is limited to integral membrane proteins; this hinders their extensive development for the purposes of targeting cancer cells. In contrast to mAbs, T cell receptors (TCRs) recognize peptides bound to major histocompatibility complex class I (MHC I) molecules. These peptides are derived from endogenously processed proteins, and therefore represent a different repertoire of targets to those recognized by mAbs. This alternate spectrum of antigens provides the potential to target cancers using an untapped source of well-validated epitopes. Naturally occurring TCRs, however, have relatively low affinities for their antigen compared to antibody binding. Advances in engineering techniques have allowed the generation of high affinity monoclonal TCRs (mTCRs) with picomolar affinities for their antigen. Using targeted mutagenesis and phage display, we have generated a number of soluble, high affinity mTCRs specific for several reported tumor-associated antigens. Through mTCR fusion to an anti-CD3 single chain variable fragment (scfv), we produced bifunctional proteins that redirect T cell immune specificity. These novel proteins are termed ImmTACs (Immune-mobilizing mTCRs Against Cancer). We present data showing the potential of two such ImmTACs, NY-ESO-ImmTAC and MAGE-A3-ImmTAC, to treat certain cancers. NY-ESO1 and MAGE-A3 are cancer testes antigens and therefore represent potentially very clean molecular targets. We demonstrate that both NY-ESO- and MAGE-A3-ImmTACs are capable of potently redirecting unstimulated CD8+ T cells against multiple myeloma, colorectal carcinoma and non-small cell lung cancer cell lines despite the presentation of extremely low antigen numbers ( Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4744. doi:10.1158/1538-7445.AM2011-4744

A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity

Targeting activity of a TCR/IL-2 fusion protein against established tumors

Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers

Bi-specific TCR anti-CD3 fusions for cancer immunotherapy (53.19)

A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function

A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity

Tumor-Targeted Delivery of IL-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2

A Single-Chain Il-12 Igg3 Antibody Fusion Protein Retains Antibody Specificity and Il-12 Bioactivity and Demonstrates Antitumor Activity

A Novel Bifunctional Fusion Protein Comprising of TGF-βRII trap and IL15/IL-15Rα as an Immunotherapeutic against Cancer

Soluble, High Affinity Tcrs Fused To Anti-Cd3 Redirect T Cells To Kill Cancer Cells Presenting Mage-A3 And Ny-Eso Antigens

A Cytokine Receptor-Masked IL2 Prodrug Selectively Activates Tumor-Infiltrating Lymphocytes for Potent Antitumor Therapy

Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma

A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells

THE STUDY OF EXPRESSION AND FUNCTION OF ANTIBODY-CYTOKINE FUSION PROTEIN 183B2scfv-Interleukin 2

Abstract 2752: Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived from HLA Transgenic RenMiceTM

High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity

Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity

Abstract 3598: A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engager